RxDoctor Payments Data

Mahlon Soloway, MD

Ophthalmology · Santa Fe, NMNPI 1407841927

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 42.4% of the total. That places this record below the midpoint for ophthalmology clinicians in NM, where the typical reported total is $868.

$461in general payments, 2019–2025

Across 14 payments — averaging $32.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$195
  • Dompe US, Inc.$117
  • AbbVie$66
  • Tarsus Pharmaceuticals, Inc.$63
  • Alcon$19

What the payments were for

  • Food & beverage$461100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$461 in reported general payments places this provider in the 35th percentile of 81 ophthalmology providers in New Mexico.

See all ophthalmology providers in New Mexico

Medicare billing

Part B allowed, 2024
$440,641
Medicare patients
2,500
Services billed
4,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost230$90,746
RestasisCyclosporine69$53,274
XiidraLifitegrast51$50,589
Cyclosporine54$24,439
Latanoprost695$9,835
Brimonidine Tartrate83$8,360
Fluorometholone69$4,368
Timolol Maleate236$3,630
Travoprost18$3,516
Brinzolamide16$2,841
Bimatoprost30$2,324
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat130$2,245
Prednisolone Acetate52$1,775
Azelastine Hcl30$886
Dorzolamide Hcl58$884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$66$144,020299 claims
Bausch & Lomb Americas Inc.Xiidra$195$50,58951 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 81 ophthalmology providers in New Mexico.

Other ophthalmology in Santa Fe

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →